Revance to Participate in Upcoming Investor Conferences
Revance management is scheduled to present at the Jefferies 2015 Healthcare Conference in
Revance management is also scheduled to present at the William Blair 2015
Interested parties can access the live audio webcast for both of these conference presentations at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
About
Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance’s proprietary TransMTS technology enables delivery of botulinum toxin A through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. Revance is pursuing clinical development for product candidates topical RT001 and injectable RT002 in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights
for all indications of RT001, RT002 and the TransMTS technology platform. More information on
“Revance Therapeutics”, TransMTS® and the Revance logo are registered trademarks of
CONTACT: Investors:Revance Therapeutics Jeanie Herbert (714) 325-3584 jherbert@revance.comWestwicke Partners Leigh Salvo (415) 513-1281 leigh.salvo@westwicke.com Trade Media: Nadine Tosk (847) 920-9858 nadinepr@gmail.com
Source:
News Provided by Acquire Media